GlassScriptPhysician profile
David Gboloo
NPI 1528163326
$8,674.23
in general payments reported to CMS, 2019-2025
48 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $813 · 2021: $1,548 · 2022: $1,019 · 2023: $1,176 · 2024: $1,680 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,613.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.59 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $796.05 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $698.33 | 2021-2025 | Freestyle Libre 3, Infinity, Proclaim |
| Glaxosmithkline, LLC. | $698.30 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $581.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $504.63 | 2022-2025 | Caplyta |
| Pfizer INC. | $487.85 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.01 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $304.62 | 2020-2022 | |
| Novo Nordisk INC | $270.38 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $239.36 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $220.53 | 2019-2025 | Qelbree |
| Allergan, INC. | $182.44 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $143.37 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $134.18 | 2022-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $120.32 | 2021-2022 | |
| Axsome Therapeutics, INC. | $92.63 | 2024-2025 | Auvelity |
| Amgen INC. | $84.94 | 2019-2024 | Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $80.66 | 2025 | Fanapt |
| Dexcom, INC. | $75.89 | 2024-2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $72.19 | 2019-2021 | |
| Ardelyx, INC. | $71.08 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $63.40 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi-Aventis U.S. LLC | $61.06 | 2020-2021 | |
| Corcept Therapeutics | $56.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.75 | 2024-2025 | Xifaxan |
| Cequr Corporation | $46.44 | 2024-2025 | Cequr Simplicity |
| Sunovion Pharmaceuticals INC. | $46.01 | 2019-2020 | |
| Astellas Pharma US INC | $44.59 | 2019-2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $42.14 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $41.49 | 2024-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $35.62 | 2022 | |
| Insulet Corporation | $34.64 | 2024-2025 | Omnipod |
| Global Blood Therapeutics, INC. | $24.55 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $22.14 | 2023 | Pyrukynd |
| Scilex Pharmaceuticals INC. | $21.64 | 2022 | |
| Ironwood Pharmaceuticals, INC | $21.32 | 2024 | |
| Corium, LLC | $21.25 | 2023 | Azstarys |
| Abiomed | $20.35 | 2025 | |
| Smith+Nephew, INC. | $18.14 | 2020 | |
| Dynavax Technologies Corporation | $17.55 | 2025 | Heplisav-B |
| Currax Pharmaceuticals LLC | $16.56 | 2024 | Onzetra Xsail, Contrave |
| Biogen, INC. | $16.44 | 2025 | Skyclarys |
| Shield Therapeutics INC | $14.78 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2025 | Zoryve |
| Vertex Pharmaceuticals Incorporated | $14.08 | 2025 | |
| Eisai INC. | $13.65 | 2022 | |
| Amarin Pharma, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gboloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.